GlassScriptPhysician profile
Scott Cory Stuart
NPI 1528533296
$6,715.01
in general payments reported to CMS, 2019-2025
25 companies · $747 in 2025
The $747 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $280 · 2022: $580 · 2023: $837 · 2024: $4,271 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,442 · Food and Beverage: $1,926 · Travel and Lodging: $1,106 · Education: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,442.00 |
| Food and Beverage | $1,925.84 |
| Travel and Lodging | $1,106.32 |
| Education | $381.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,787.72 | 2021-2024 | |
| Janssen Biotech, INC. | $512.26 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $396.09 | 2021-2025 | |
| Ucb, INC. | $279.85 | 2021-2025 | Bimzelx |
| Amgen INC. | $256.00 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $253.51 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $171.35 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $154.24 | 2022-2023 | |
| Kyowa Kirin, INC. | $119.77 | 2021-2022 | |
| Incyte Corporation | $100.61 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $98.04 | 2024-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $79.75 | 2022-2024 | Dupixent |
| Dermavant Sciences, INC. | $71.27 | 2023-2024 | Vtama |
| Organogenesis INC. | $69.03 | 2021-2025 | Puraply, Via Matrix |
| Novartis Pharmaceuticals Corporation | $59.95 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $49.05 | 2024-2025 | Vtama |
| Vyne Pharmaceuticals INC. | $47.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.78 | 2024-2025 | Spevigo |
| Merz North America, INC. | $40.82 | 2022-2023 | Xeomin |
| Sun Pharmaceutical Industries INC. | $35.12 | 2023 | Odomzo, Blu-U, Absorica Ld |
| Mimedx Group, INC. | $24.54 | 2024 | |
| Urgo Medical North America, LLC | $20.79 | 2025 | Urgok2 |
| Boston Scientific Corporation | $15.25 | 2025 | Intracept |
| Arcutis Biotherapeutics, INC. | $15.22 | 2023 | |
| Galderma Laboratories, L.P. | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.